Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

CenExel announces its role in Vertex Pharma’s studies in Journavx and celebrates US FDA approval: Salt Lake City, Utah Saturday, February 8, 2025, 14:00 Hrs [IST] CenExel, a lea ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The US Food and Drug Administration has approved suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid ...

While Journavx (suzetrigine) significantly reduced pain after 12 weeks, so, too, did placebo. The difference between placebo and Journavx was nominal. Vertex attributed the glaring lack of ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...